Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Augusta, Kansas Clinical Trials

A listing of Augusta, Kansas clinical trials actively recruiting patient volunteers.

RESULTS

Found (6) clinical trials

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

This is a 2-stage, phase 1/2, randomized, active-controlled, observer-blinded study with a 2-arm parallel design in each stage. In Stage 1 healthy adults 50 to 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Efficacy Safety and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

The purpose of this study is to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Phase

0.68 miles

Learn More »

Open Label Safety Study in Acute Treatment of Migraine

The purpose of this study is to evaluate safety and tolerability of BHV3000 (rimegepant).

Phase

0.68 miles

Learn More »

Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children (V210-A03)

This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX (Varicella Virus Vaccine Live) manufactured with a new passage extension (PE34) process compared with the VARIVAX 2016 commercial process. The primary hypotheses being tested are that antibody response rate and mean antibody titer induced at 6 weeks after a ...

Phase

0.68 miles

Learn More »

Trial in Adult Subjects With Acute Migraines

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.

Phase

0.68 miles

Learn More »

Safety Tolerability and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

This study will evaluate the safety, tolerability, and efficacy of Human Cytomegalovirus (CMV) vaccine V160 administered in a 2-dose or 3-dose regimen in healthy seronegative women 16 to 35 years of age. Participants will receive blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day ...

Phase

0.68 miles

Learn More »